| Phase 13 trials |
|
Phase 1
|
NCT07152288 |
May → Sep 2025 overdue |
paroxysmal nocturnal hemoglobinuria |
Haisco Pharmaceutical Group Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT06852092 |
Sep 2024 |
paroxysmal nocturnal hemoglobinuria |
Haisco Pharmaceutical Group Co., Ltd. |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT06350279 |
Dec 2023 → Aug 2024 |
— |
Haisco Pharmaceutical Group Co., Ltd. |
Completed
|
No outcome recorded
|
| Phase 23 trials |
|
Phase 2
|
NCT06745622 |
Jan 2025 → Jun 2027 expected |
paroxysmal nocturnal hemoglobinuria |
Haisco Pharmaceutical Group Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06670352 |
Oct 2024 → Dec 2025 |
IgA glomerulonephritis |
Haisco Pharmaceutical Group Co., Ltd. |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT06561841 |
Jul 2024 → Apr 2025 |
paroxysmal nocturnal hemoglobinuria |
Haisco Pharmaceutical Group Co., Ltd. |
Completed
|
No outcome recorded
|
| Phase 33 trials |
|
Phase 3
|
NCT07390123 |
Apr 2026 → Dec 2027 expected |
IgA glomerulonephritis |
Haisco Pharmaceutical Group Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT07052838 |
May → Dec 2025 |
paroxysmal nocturnal hemoglobinuria |
Haisco Pharmaceutical Group Co., Ltd. |
Completed
|
No outcome recorded
|
|
Phase 3
|
NCT06799546 |
Feb → Nov 2025 |
paroxysmal nocturnal hemoglobinuria |
Haisco Pharmaceutical Group Co., Ltd. |
Completed
|
No outcome recorded
|
| Comparator or background therapy2 trials |
|
Phase 2
|
NCT07363460 Comparator |
Nov 2025 → Nov 2027 expected |
lupus nephritis |
Haisco Pharmaceutical Group Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT07616700 Comparator |
Aug 2025 → Dec 2026 expected |
IgA glomerulonephritis |
Haisco Pharmaceutical Group Co., Ltd. |
Recruiting
|
No outcome recorded
|